Gonorrhea & Chlamydia — 2025 Treatment Guidance

Key Points

• Gonorrhea and chlamydia are common bacterial sexually transmitted infections that are frequently asymptomatic.
• Ask about symptoms, pregnancy, anatomic exposures, partner gender and practices without assumptions, prior STIs, allergy, and treatment access.
• Current CDC treatment for uncomplicated gonorrhea is ceftriaxone 500 mg IM once for patients weighing less than 150 kg and 1 g IM once for those weighing at least 150 kg.
• Use NAAT at exposed sites and other targeted evaluation to answer specific diagnostic or safety questions rather than ordering broad testing without a plan.
• Escalate urgently for pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain.
• Other major warning findings include suspected gonorrhea treatment failure after appropriate therapy and no re-exposure and pharyngeal gonorrhea without a plan for test of cure or untreated recent partners.
• Medication and procedural choices should be matched to physiology, contraindications, renal/hepatic function, pregnancy status, and interaction risk when relevant.
• Ensure recent sex partners are evaluated and treated; expedited partner therapy can be used where legal and clinically appropriate.

Algorithm

1. Confirm that the presentation is consistent with Gonorrhea & Chlamydia — 2025 Treatment Guidance and identify immediately life-threatening alternatives or complications.
2. Obtain a focused history and examination that define severity, mechanism, relevant comorbidity, prior treatment, and baseline function.
3. Use targeted evaluation such as NAAT at exposed sites, Gonorrhea culture + susceptibility, and other tests only when they can change management.
4. Classify the patient into a treatment pathway based on stability, disease/procedure subtype, organ function, and the presence or absence of escalation findings.
5. Begin the first-line intervention described for Gonorrhea & Chlamydia — 2025 Treatment Guidance, using the least complex safe regimen that directly treats the mechanism.
6. Reassess symptoms, vital signs, examination, laboratory or imaging response, and treatment toxicity after the first clinically meaningful interval.
7. Stop routine progression and escalate care for pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain, suspected gonorrhea treatment failure after appropriate therapy and no re-exposure, or pharyngeal gonorrhea without a plan for test of cure or untreated recent partners.
8. At discharge or transition, document the final diagnosis, remaining uncertainty, medication/procedure plan, follow-up timing, prevention strategy, and explicit return precautions.

Clinical Synopsis & Reasoning

Gonorrhea and chlamydia are common bacterial sexually transmitted infections that are frequently asymptomatic. Diagnosis and treatment should account for the anatomic sites exposed—urogenital, rectal, and pharyngeal—because urine testing alone can miss extragenital infection. Nucleic acid amplification testing is preferred at each exposed site.

Ask about symptoms, pregnancy, anatomic exposures, partner gender and practices without assumptions, prior STIs, allergy, and treatment access. Obtain NAAT from urine/vaginal/cervical specimens and rectal/pharyngeal sites based on exposure. Test for HIV and syphilis and offer HIV PrEP when appropriate. Culture with susceptibility testing is important when gonorrhea treatment failure or antimicrobial resistance is suspected.

The practical diagnostic task is to decide what must be established immediately, what can be clarified after stabilization, and which finding would change the working diagnosis. Useful evaluation elements include NAAT at exposed sites, Gonorrhea culture + susceptibility, Pregnancy test, HIV and syphilis testing. Each test should answer a defined question rather than be ordered reflexively. Serial examination is especially important when early results can be normal or when treatment itself changes the physiology being measured.

Infectious-disease management combines syndrome recognition, microbiology, source control, antimicrobial selection, and stewardship. The narrowest effective regimen should be used once the likely or confirmed pathogen is known. For Gonorrhea & Chlamydia — 2025 Treatment Guidance, the clinician should explicitly separate expected findings from escalation findings such as pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain, suspected gonorrhea treatment failure after appropriate therapy and no re-exposure, or pharyngeal gonorrhea without a plan for test of cure or untreated recent partners.

Treatment Strategy & Disposition

Current CDC treatment for uncomplicated gonorrhea is ceftriaxone 500 mg IM once for patients weighing less than 150 kg and 1 g IM once for those weighing at least 150 kg. If chlamydia has not been excluded, add doxycycline 100 mg orally twice daily for 7 days in nonpregnant patients. Uncomplicated chlamydia is treated with doxycycline 100 mg twice daily for 7 days; in pregnancy, azithromycin 1 g orally once is the standard recommended regimen. Pharyngeal gonorrhea requires test of cure 7-14 days after treatment. Routine test of cure is not needed after uncomplicated urogenital/rectal gonorrhea treated with a recommended regimen, but all patients should be retested in about 3 months because reinfection is common.

Ensure recent sex partners are evaluated and treated; expedited partner therapy can be used where legal and clinically appropriate. Advise abstinence for 7 days after single-dose therapy or until completion of a 7-day regimen and until partners have been treated. Retest at about 3 months.

Treatment should be reassessed after the first meaningful intervention rather than allowed to continue automatically. Relevant medications or therapeutic agents in this topic include Ceftriaxone IM, Doxycycline, Azithromycin, Alternative gonorrhea regimens. Their usefulness depends on the indication, patient physiology, and contraindications shown in the sections below. If the response is poorer than expected, revisit the diagnosis, treatment delivery, adherence or access, procedure success when relevant, and the possibility of a complication.

Diagnostic specimens are most valuable when collected correctly and when the result can change therapy; broad testing without a clinical question can create false positives and unnecessary treatment. Follow-up must include treatment response, complications, transmission prevention when relevant, vaccination or prevention opportunities, and a plan for treatment failure.

Epidemiology / Risk Factors

• Gonorrhea & Chlamydia — 2025 Treatment Guidance is an important infectious-disease topic because timely treatment must be balanced with diagnostic accuracy and antimicrobial stewardship.
• Risk depends on host factors, anatomic site, severity, prior antimicrobial exposure, and the probability of resistant or complicated infection.
• Prevention, transmission control when relevant, and recognition of treatment failure are essential to reducing recurrence and complications.

Investigations

2025-2026 STI Dosing Summary

Pharmacology

Prognosis / Complications

• Outcome in Gonorrhea & Chlamydia — 2025 Treatment Guidance depends on baseline severity, underlying mechanism, comorbidity, speed of appropriate treatment, and whether major complications develop.
• Patients who respond as expected still need follow-up focused on recurrence prevention, treatment adverse effects, and restoration of function or physiologic stability.
• The appearance of pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain or suspected gonorrhea treatment failure after appropriate therapy and no re-exposure changes prognosis and should prompt a higher-acuity reassessment rather than routine outpatient progression.
• A durable plan is one that the patient can follow outside the clinical setting and that includes clear thresholds for returning to care.

Patient Education / Counseling

• Explain the diagnosis of Gonorrhea & Chlamydia — 2025 Treatment Guidance in plain language, including what is known, what remains uncertain, and what the immediate treatment is intended to accomplish.
• Review how the patient should take or use the recommended therapy and what common adverse effects or practical barriers to expect.
• Explain that worsening symptoms are not always a normal part of recovery and give specific return precautions for pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain.
• Also seek prompt care for suspected gonorrhea treatment failure after appropriate therapy and no re-exposure or pharyngeal gonorrhea without a plan for test of cure or untreated recent partners.
• Discuss prevention or risk reduction relevant to the condition, including medication adherence, follow-up testing, rehabilitation, vaccination, sexual/partner management, or lifestyle factors as appropriate.
• Use teach-back at discharge so the patient or caregiver can state the treatment plan, follow-up timing, and reasons to return.

Notes

The main practical error in Gonorrhea & Chlamydia — 2025 Treatment Guidance is to reduce the topic to a memorized list without linking each action to a clinical purpose. A safer approach identifies the decision point, chooses the test or intervention that changes that decision, and then reassesses whether the patient is moving in the expected direction. Findings such as pelvic inflammatory disease, epididymitis, disseminated gonococcal infection, septic arthritis, pregnancy complication, or severe pelvic/testicular pain, suspected gonorrhea treatment failure after appropriate therapy and no re-exposure, and pharyngeal gonorrhea without a plan for test of cure or untreated recent partners should move the patient out of a routine pathway and into higher-acuity diagnostic or specialty assessment.

Documentation should make the reasoning reproducible. Record the baseline state, the key evidence supporting the diagnosis, major alternatives that were addressed, treatment actually delivered, response, and the follow-up responsibility. This is particularly important when multiple clinicians will share care or when a procedure, high-risk medication, evolving laboratory abnormality, or time-sensitive infection/vascular syndrome is involved. Once the patient is stable, the remaining work is prevention: address modifiable risk, treatment access, adherence, functional recovery, and the specific complication most likely to cause return to care.

References

1. CDC - STI Treatment Guidelines: Gonorrhea and Chlamydia — Link
2. Infectious Diseases Society of America - Practice Guidelines — Link
3. CDC - Clinical Guidance — Link